Breaking News Instant updates and real-time market news.

AGEN

Agenus

$4.33

-0.14 (-3.13%)

, GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

10:15
10/21/17
10/21
10:15
10/21/17
10:15

FDA approves GlaxoSmithKline shingles vaccine with Agenus QS-21 Stimulon

Agenus (AGEN) has announced that the Food and Drug Administration granted marketing authorization to GlaxoSmithKline's (GSK) herpes zoster vaccine, SHINGRIX, containing Agenus' proprietary immune adjuvant QS-21 Stimulon. SHINGRIX is indicated for prevention of herpes zoster - also known as shingles - in adults aged 50 years and older. The addition of QS-21 Stimulon helps improve the vaccine's effectiveness by boosting immune response in older adults who often experience age-related decline in immunity. The FDA approval of SHINGRIX was based on data pooled from two pivotal Phase III clinical trials in more than 37,000 people, which demonstrated an efficacy rate against shingles greater than 90% independent of age, as well as a sustained efficacy over the four-year follow-up period. SHINGRIX also reduced the overall incidence of postherpetic neuralgia, the most common and oftentimes debilitating chronic nerve pain associated with shingles. The most common side effects reported in clinical trials of SHINGRIX were pain, redness and swelling at the injection site, the majority of which were transient and mild to moderate in intensity, lasting less than three days. The addition of QS-21 Stimulon is being studied to determine its potential to help a diverse range of vaccines work more effectively to treat or cure difficult-to-treat diseases, like cancer. QS-21 Stimulon is currently being used in combination with Agenus' neoantigen vaccine, AutoSynVax, now in a Phase 1 clinical trial in cancer. QS-21 Stimulon is also currently being evaluated in numerous GlaxoSmithKline vaccine development candidates for both therapeutic and prophylactic applications.

AGEN

Agenus

$4.33

-0.14 (-3.13%)

GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

AGEN Agenus
$4.33

-0.14 (-3.13%)

10/28/16
HCWC
10/28/16
DOWNGRADE
Target $5
HCWC
Neutral
Agenus downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Agenus to Neutral saying any significant clinical results are at least 12-18 months away. The analyst expects the stock to be range bound given a lack of catalysts. He cut his price target for the shares to $5 from $10.
GSK GlaxoSmithKline
$40.84

-0.26 (-0.63%)

07/10/17
PIPR
07/10/17
NO CHANGE
Target $5
PIPR
Neutral
OncoMed termination from GSK not surprising, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes GlaxoSmithKline (GSK) terminating its agreement with OncoMed Pharmaceuticals (OMED) is not surprising since tarextumab, the only remaining asset under the collaboration, failed previously to meet the primary endpoint in a Phase II study for first-line small cell lung cancer. The analyst says he remains focused on OncoMed's early stage pipeline including navicixizumab, rosmantuzumab and I/O assets anti-TIGIT and GITR trimer. Tenthoff keeps a Neutral rating on OncoMed with a $5 price target.
08/30/17
ARGS
08/30/17
NO CHANGE
ARGS
GlaxoSmithKline weakness creates buying opportunity, says Argus
Argus analyst John Eade says that the 8% decline in GlaxoSmithKline's stock over the past quarter has created a buying opportunity. The analyst expects the company's profits to rise by low single percentage digits in 2017 and 2018, and he calls its 5% dividend yield attractive.
09/08/17
MSCO
09/08/17
DOWNGRADE
MSCO
Underweight
GlaxoSmithKline downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier downgraded GlaxoSmithKline to Underweight saying its 2020 roadmap appears "challenging" given capital allocation constraints and low R&D optionality.
10/16/17
JEFF
10/16/17
NO CHANGE
Target $115
JEFF
Buy
Jefferies ups price target on top global pick AbbVie to $115
Jefferies analyst Jeffrey Holford keeps AbbVie (ABBV) as his top global Pharmaceuticals pick for October, followed by Roche (RHHBY), Novartis (NVS), Bayer (BAYRY), Johnson & Johnson (JNJ), Eli Lilly (LLY) and GlaxoSmithKline (GSK). The analyst raised his price target for AbbVie shares to $115 from $107 and keeps a Buy rating on the name. Among his other target changes include bumping Eli Lilly's to $100 from $96.

TODAY'S FREE FLY STORIES

GE

General Electric

$17.88

-0.105 (-0.58%)

14:20
11/21/17
11/21
14:20
11/21/17
14:20
Options
Repeat action in GE »

Repeat action in GE. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/21/17
11/21
14:17
11/21/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/21/17
11/21
14:16
11/21/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$34.91

-0.21 (-0.60%)

, PFE

Pfizer

$35.61

0.2648 (0.75%)

14:05
11/21/17
11/21
14:05
11/21/17
14:05
Hot Stocks
FDA approves ViiV Healthcare's two drug HIV treatment Juluca »

The FDA today said it…

GSK

GlaxoSmithKline

$34.91

-0.21 (-0.60%)

PFE

Pfizer

$35.61

0.2648 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 07

    Dec

  • 14

    Dec

OCLR

Oclaro

$6.49

-0.09 (-1.37%)

14:05
11/21/17
11/21
14:05
11/21/17
14:05
Options
Oclaro call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 12

    Dec

NUE

Nucor

$56.02

0.46 (0.83%)

14:04
11/21/17
11/21
14:04
11/21/17
14:04
Hot Stocks
Nucor announces plans to build rebar micro mill »

Nucor announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

14:01
11/21/17
11/21
14:01
11/21/17
14:01
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

13:59
11/21/17
11/21
13:59
11/21/17
13:59
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SSNLF

Samsung

, WHR

Whirlpool

$166.91

1.71 (1.04%)

13:58
11/21/17
11/21
13:58
11/21/17
13:58
Periodicals
ITC calls for tariff-rate quota on imported Samsung, LG washers, Reuters says »

The U.S. International…

SSNLF

Samsung

WHR

Whirlpool

$166.91

1.71 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RF

Regions Financial

$15.70

-0.16 (-1.01%)

13:55
11/21/17
11/21
13:55
11/21/17
13:55
Options
Regions Financial put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLMT

Calumet Specialty Products

$8.30

0.1 (1.22%)

13:53
11/21/17
11/21
13:53
11/21/17
13:53
Hot Stocks
Calumet Specialty Products announces divestiture of Anchor Drilling Fluids »

Calumet Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITUS

ITUS

$3.16

0.25 (8.59%)

13:53
11/21/17
11/21
13:53
11/21/17
13:53
Conference/Events
ITUS to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

$15.03

-0.0315 (-0.21%)

13:49
11/21/17
11/21
13:49
11/21/17
13:49
Downgrade
Enable Midstream rating change  »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLY

Stanley Furniture

$0.93

0.0349 (3.92%)

13:47
11/21/17
11/21
13:47
11/21/17
13:47
Hot Stocks
Stanley Furniture to sell substantially all its assets »

As previously reported,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
11/21/17
11/21
13:40
11/21/17
13:40
General news
NY Fed's overnight reverse repo totaled $42.9 B (19 counterparties) »

NY Fed's overnight…

EYE

National Vision

$30.19

0.21 (0.70%)

13:33
11/21/17
11/21
13:33
11/21/17
13:33
Initiation
National Vision initiated  »

National Vision initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

13:32
11/21/17
11/21
13:32
11/21/17
13:32
Downgrade
Cytokinetics rating change  »

Cytokinetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

LOW

Lowe's

$81.59

0.13 (0.16%)

13:27
11/21/17
11/21
13:27
11/21/17
13:27
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

WHR

Whirlpool

$165.67

0.47 (0.28%)

13:25
11/21/17
11/21
13:25
11/21/17
13:25
Periodicals
ITC suggests tariffs on washing machine imports above 1.2M units, Bloomberg says »

Two of four ITC officials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWI

Armstrong World

$53.70

-0.15 (-0.28%)

13:25
11/21/17
11/21
13:25
11/21/17
13:25
Conference/Events
Armstrong World to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BMO

Bank of Montreal

$77.39

0.06 (0.08%)

13:21
11/21/17
11/21
13:21
11/21/17
13:21
Hot Stocks
BMO Financial Group enters partnership with CDL-Montreal »

BMO Financial Group and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
11/21/17
11/21
13:20
11/21/17
13:20
General news
Fed Governor Powell's hearings for the position as Fed Chair »

Fed Governor…

PG

Procter & Gamble

$88.93

0.66 (0.75%)

13:20
11/21/17
11/21
13:20
11/21/17
13:20
Options
Buyer lays out 500K for three month upside in Procter and Gamble »

Buyer lays out 500K for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
11/21/17
11/21
13:17
11/21/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/21/17
11/21
13:16
11/21/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.